Dicerna Pharmaceuticals, Inc.
DRNA
DRNA was delisted on the 27th of December, 2021.
144 hedge funds and large institutions have $1.13B invested in Dicerna Pharmaceuticals, Inc. in 2020 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 52 increasing their positions, 53 reducing their positions, and 37 closing their positions.
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
2% less repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 53
11% less capital invested
Capital invested by funds: $1.27B → $1.13B (-$140M)
15% less funds holding
Funds holding: 169 → 144 (-25)
62% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 37
75% less call options, than puts
Call options by funds: $292K | Put options by funds: $1.15M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$70M |
| 2 |
RI
RTW Investments
New York
|
+$21.2M |
| 3 |
BlackRock
New York
|
+$12.2M |
| 4 |
ACM
Aquilo Capital Management
San Francisco,
California
|
+$12.1M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$8.63M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$14.2M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$12.7M |
| 3 |
AG
Artal Group
Luxembourg
|
-$11M |
| 4 |
BM
Bridger Management
New York
|
-$5.88M |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
-$5.47M |
DRNA Hedge Fund Activity: Q1 2020 in Review
144 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Dicerna Pharmaceuticals, Inc. (DRNA) for Q1 2020, worth a combined $1.13B — down 11% from $1.27B a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of DRNA and 14 opened new positions — a net loss of 23 holders — while 53 trimmed existing stakes and 52 added.
The largest buyer was Wellington Management Group, adding an estimated $70M. The largest seller was Marshall Wace, cutting an estimated $14.2M.
- 144 institutional investors held Dicerna Pharmaceuticals, Inc. (DRNA) as of Q1 2020, down from 169 in Q4 2019.
- Funds reported $1.13B of Dicerna Pharmaceuticals, Inc. stock for Q1 2020, down 11% quarter-over-quarter.
- 14 funds opened new Dicerna Pharmaceuticals, Inc. positions in Q1 2020 and 37 closed out, a net change of -23 holders.
- The largest Dicerna Pharmaceuticals, Inc. buyer in Q1 2020 was Wellington Management Group, an estimated $70M added.
- The largest Dicerna Pharmaceuticals, Inc. seller in Q1 2020 was Marshall Wace, an estimated $14.2M sold.
Based on aggregated 13F filings for Q1 2020.